Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients

J Clin Endocrinol Metab. 2009 Jan;94(1):181-9. doi: 10.1210/jc.2008-1806. Epub 2008 Oct 28.

Abstract

Context: Glucose-dependent insulin secretion is often impaired after islet transplantation where reduced beta-cell secretory capacity indicates a low functional beta-cell mass.

Objective: We sought to determine whether glucagon-like peptide-1 (GLP-1) enhanced glucose-dependent insulin secretion and glucagon suppression in islet recipients, and whether GLP-1 effects were dependent on functional beta-cell mass by simultaneously studying recipients of whole pancreas transplants.

Setting: The study was performed in a clinical and translational research center.

Participants: Five intraportal islet and six portally drained pancreas transplant recipients participated in the study.

Intervention: Subjects underwent glucose-potentiated arginine testing with GLP-1 (1.5 pmol . kg(-1) . min(-1)) or placebo infused on alternate randomized occasions, with 5 g arginine injected under basal and hyperglycemic clamp conditions.

Results: Basal glucose was lower with increases in insulin and decreases in glucagon during GLP-1 vs. placebo in both groups. During the hyperglycemic clamp, a significantly greater glucose infusion rate was required with GLP-1 vs. placebo in both groups (P < 0.05), an effect more pronounced in the pancreas vs. islet group (P < 0.01). The increased glucose infusion rate was associated with significant increases in second-phase insulin secretion in both groups (P < 0.05) that also tended to be greater in the pancreas vs. islet group (P = 0.08), whereas glucagon was equivalently suppressed by the hyperglycemic clamp during GLP-1 and placebo infusions in both groups. The GLP-1-induced increase in second-phase insulin correlated with the beta-cell secretory capacity (P < 0.001). The proinsulin secretory ratio (PISR) during glucose-potentiated arginine was significantly greater with GLP-1 vs. placebo infusion in both groups (P < 0.05).

Conclusions: GLP-1 induced enhancement of glucose-dependent insulin secretion, but not glucagon suppression, in islet and pancreas transplant recipients, an effect dependent on the functional beta-cell mass that may be associated with depletion of mature beta-cell secretory granules.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Arginine / pharmacology
  • Blood Glucose / analysis
  • Female
  • Glucagon / blood
  • Glucagon-Like Peptide 1 / pharmacology*
  • Glucagon-Secreting Cells / drug effects*
  • Glucagon-Secreting Cells / physiology
  • Humans
  • Insulin / blood
  • Insulin-Secreting Cells / drug effects*
  • Insulin-Secreting Cells / physiology
  • Islets of Langerhans Transplantation*
  • Male
  • Middle Aged
  • Pancreas Transplantation*
  • Proinsulin / blood

Substances

  • Blood Glucose
  • Insulin
  • Glucagon-Like Peptide 1
  • Glucagon
  • Proinsulin
  • Arginine